Skyrizi (risankizumab-rzaa or risankizumab) is a medication that works as an interleukin antagonist to help lessen inflammation. It's used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease in adults. This medication is an injection that you typically only need to get every 2 or 3 months after the first couple doses. You can give yourself the injection at home once you get trained on how to use the medication safely and properly. Side effects might differ based on your dose and why you're taking Skyrizi (risankizumab), but can generally include joint pain and a higher risk of infections.
Moderate-to-severe plaque psoriasis
Psoriatic arthritis
Moderate-to-severe Crohn's disease
Skyrizi (risankizumab) is a monoclonal antibody that works as an interleukin antagonist. It attaches to certain proteins in your immune system called interleukin-23 (IL-23) that play a role in causing inflammation. This stops the proteins from getting turned on, which helps lower inflammation.
Source: DailyMed
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report to your care team if they continue or are bothersome):
Given every 2 or 3 months after a couple of starter doses (depends on your condition)
Available as a prefilled syringe, prefilled pen, and On-Body Injector for easier use
Can inject at home after proper training
Not approved for use in children
Only available as an injection
Might be difficult for some people to administer correctly
For treating plaque psoriasis and psoriatic arthritis: You can give yourself injections of Skyrizi (risankizumab) at home once you get trained by your provider. You'll use either the Skyrizi prefilled syringe or pen.
For treating Crohn's disease: Your provider will give your first 3 doses of Skyrizi (risankizumab) as an infusion through the vein. Be sure to schedule appointments for your infusions; each infusion takes at least 1 hour. After your starter doses, your injections will be given under the skin, and your provider might let you use the medication at home after you get trained. You'll use the Skyrizi On-Body Injector and prefilled cartridges at home.
Before you get any vaccines, tell your provider or pharmacist that you're taking Skyrizi (risankizumab). Your providers can make sure the vaccines are safe for you to get. It's not known whether the medication affects how your body responds to vaccines.
Tips for using Skyrizi (risankizumab) at home
Your healthcare team will train you on how to use Skyrizi (risankizumab) at home. Make sure you know how to safely and properly give yourself injections. As a refresher, be sure to read the instructions for the Skyrizi prefilled syringe or pen or the On-Body Injector. Ask your providers if you have any questions on how to use Skyrizi (risankizumab).
Keep Skyrizi (risankizumab) in the original carton to protect it from light and place it in the refrigerator.
When you're ready for your dose, take the Skyrizi (risankizumab) carton out of the refrigerator (without taking out the pen, syringe, cartridge, or On-Body Injector from the carton). Lay it on a flat surface to warm up; this should take about 15 to 90 minutes, depending on the device you're using. Don't try to warm up the medication any other way.
Skyrizi (risankizumab) is injected under the skin at the front of your thighs or stomach (at least 2 inches from your belly button). For the Skyrizi prefilled pen or syringe, you can also ask someone to help inject the medication under the skin at the back of your upper arms. Never inject it into your muscle or vein.
Skyrizi prefilled pen: Your injection is complete when the pen makes a second "click" or when the yellow indicator fills the inspection window. An injection can take up to 15 seconds.
Skyrizi prefilled syringe: The prefilled syringes come in two strengths (150 mg/mL and 75 mg/0.83 mL). If you're using the 75 mg/0.83 mL strength, you'll need two 75 mg injections, one after the other, to make your 150 mg dose. Use a different area of skin for each injection. Each injection is complete when you see that the syringe is empty, the plunger rod is pushed all the way in, and the whole needle is covered by the needle guard.
Skyrizi On-Body Injector: It can take up to 5 minutes to complete a full injection, and the On-Body Injector will stop by itself. You'll know when your injection is done when you hear beeps and when the status light becomes solid green (not flashing).
After your injection, place your Skyrizi device in a sharps container or a heavy-duty plastic container (e.g., empty milk carton, laundry detergent bottle) to lower the risk of needle-stick injuries. Don't throw away syringes, needles, or On-Body Injectors into your trash can. Visit the FDA's website for guidance on how to safely throw away your sharps container in your specific state.
Skyrizi (risankizumab) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
It's possible to have a serious allergic reaction to Skyrizi (risankizumab). These allergic reactions can include difficulty breathing; hives; swelling of your face, lips, tongue, or throat; or any other symptom of anaphylaxis. Get medical help right away if you have an allergic reaction to Skyrizi (risankizumab) at any time during treatment.
Risk factors: Active, chronic, or recurrent infection | Having other conditions that raise your risk of infection
Skyrizi (risankizumab) can affect your body's ability to fight off germs and raise your risk for bacterial, viral, or fungal infections. In clinical studies, people most commonly reported upper respiratory infections and fungal infections.
Skyrizi (risankizumab) can also cause new or old tuberculosis (TB) infections to come back. You'll need to get tested for TB before you start this medication and get treated if it's confirmed that you have TB. Tell your provider about your medical conditions and medications to make sure Skyrizi (risankizumab) is safe to take.
Contact your provider if you develop symptoms of an infection, such as fever; cough; difficulty breathing; diarrhea; weakness; sweating; chills; or itchy, scaly, or burning skin). Your provider can examine you to see whether you have an infection. If you do, you might have to stop taking Skyrizi (risankizumab) so your body can fight the infection.
Avoid getting live vaccines because it's not known whether they're safe to get while you're taking Skyrizi (risankizumab). Examples of live vaccines include Varivax (chickenpox vaccine) and MMR (measles, mumps, and rubella vaccine). It's best to be up to date on all your vaccines before you start Skyrizi (risankizumab). Let your provider or pharmacist know that you're taking Skyrizi (risankizumab) before you get any vaccines.
So far, one person with Crohn's disease has had serious liver injury after getting a couple doses of Skyrizi (risankizumab) infused through the vein. Tell your provider if you have any liver problems along with Crohn's disease before starting this medication to make sure it's safe for you. Although liver injury is rare, your provider might order blood tests to check your liver health when you first start Skyrizi (risankizumab) for Crohn's disease. Get medical attention right away if you have any symptoms of liver injury, such as stomach pain, nausea, or yellowing of the skin or whites of the eyes.
Plaque psoriasis and psoriatic arthritis: The typical starting dose is 150 mg injected under the skin once every month for the first 2 doses. Then, it's given once every 3 months.
Crohn's disease: The typical starting dose is 600 mg infused through the veins (intravenous or IV) once every month for the first 3 doses. Then one month later, the dose changes to 180 mg or 360 mg injected under the skin that's given once every 2 months.
Moderate-to-severe plaque psoriasis
Psoriatic arthritis
Moderate-to-severe Crohn's disease
Moderate-to-severe Crohn's disease
Moderate-to-severe rheumatoid arthritis (RA)
Moderate-to-severe plaque psoriasis (PsO)
Rheumatoid arthritis (RA) - adults only
Juvenile idiopathic arthritis (JIA) - people age 2 and older
Psoriatic arthritis (PsA) - adults only
Ankylosing spondylitis (AS) - adults only
Crohn's disease (CD) - people age 6 and older
Ulcerative colitis (UC) - people age 5 and older
Plaque psoriasis - adults only
Hidradenitis suppurativa (HS) - people age 12 and older
Uveitis - people age 2 and older
By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.
AbbVie. (2022). Step-by-step guide to using your Skyrizi on-body injector.
Abbvie. (2023). Quick tips for self-injecting at home.
Abbvie (2023). Quick tips for self-injecting at home.
AbbVie. (2023). Skyrizi- risankizumab-rzaa kit; risankizumab-rzaa injection [package insert]. DailyMed.
Tang, C., et al. (2012). Interleukin-23: As a drug target for autoimmune inflammatory diseases. Immunology.
U.S. Food and Drug Administration. (2021). Safely using sharps (needles and syringes) at home, at work and on travel.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.